Diaceutics PLC (LON:DXRX – Get Free Report) insider Peter Keeling sold 1,750,000 shares of the company’s stock in a transaction on Thursday, November 12th. The stock was sold at an average price of GBX 190, for a total transaction of £3,325,000.
Diaceutics Stock Performance
Shares of DXRX traded down GBX 1 during mid-day trading on Friday, reaching GBX 194. The company’s stock had a trading volume of 330,586 shares, compared to its average volume of 298,740. The business has a 50-day simple moving average of GBX 188.20 and a two-hundred day simple moving average of GBX 160.85. Diaceutics PLC has a 1-year low of GBX 125 and a 1-year high of GBX 210. The stock has a market cap of £164.85 million, a P/E ratio of -606.25 and a beta of 0.88. The company has a current ratio of 2.55, a quick ratio of 9.92 and a debt-to-equity ratio of 5.40.
Diaceutics (LON:DXRX – Get Free Report) last released its quarterly earnings data on Tuesday, September 22nd. The company reported GBX (3.27) EPS for the quarter. Diaceutics had a negative return on equity of 0.68% and a negative net margin of 0.66%. As a group, equities research analysts anticipate that Diaceutics PLC will post 1.01 earnings per share for the current fiscal year.
Analyst Ratings Changes
Separately, Canaccord Genuity Group reissued a “buy” rating and issued a GBX 215 target price on shares of Diaceutics in a research report on Tuesday. Two equities research analysts have rated the stock with a Buy rating. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of GBX 215.
View Our Latest Stock Report on DXRX
Diaceutics Company Profile
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.
Featured Articles
- Five stocks we like better than Diaceutics
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
- Firefly Aerospace Lights Up a High-Risk Space Opportunity
- Is Buying the NVIDIA Dip a Mistake? 3 Value Stocks Offer a Different Path Forward
Receive News & Ratings for Diaceutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diaceutics and related companies with MarketBeat.com's FREE daily email newsletter.
